A. Quiñones-Hinojosa

Intracranial Targeting of Cholesterol Processing Reveals a Therapeutic Vulnerability that Reprograms Glioblastoma and Promotes Antitumor Immunity

These findings establish cholesterol dysregulation–induced metabolic collapse as a promising therapeutic approach for GBM using two FDA-approved drugs: the H1 histamine antagonist clemastine and the retinoid X receptor agonist bexarotene.